Replies to post #210364 on Biotech Values

[DewDiligence]

ACOR’s PR on patent ruling:

http://finance.yahoo.com/news/u-district-court-issues-decision-163100581.html

Acorda Therapeutics, Inc…today announced that the United States District Court for the District of Delaware upheld U.S. Patent No. 5,540,938 (the ‘938 patent), which pertains to the formulation of AMPYRA (dalfampridine) Extended Release Tablets, 10 mg and is set to expire in July 2018.

The Court invalidated U.S. Patent Nos. 8,663,685 (the ‘685 patent), 8,007,826 (the ‘826 patent), 8,440,703 (the ‘703 patent), and 8,354,437 (the ‘437 patent) which pertain to AMPYRA. The Company will appeal the ruling on these patents.

…The Company has developed contingency plans to address its business needs and objectives in the event of a loss of AMPYRA exclusivity, and will provide an update after finalizing the implementation timeline.

The bottom paragraph is silly, but ACOR does have at least 15 months until generic versions of Ampyra hit the US market.